Home >> General Pharmaceuticals >> Housing >> Food & Beverage >>

Longevity Biotech, Inc - Product Pipeline Review - 2015

Published: Feb-2015 | Format: PDF | Global Markets Direct | Number of pages: 29 | Code: MRS - 7035

 

Global Markets Direct’s, ‘Longevity Biotech, Inc Product Pipeline Review 2015’, provides an overview of the Longevity Biotech, Inc’s pharmaceutical research and development focus.

 

This report provides comprehensive information on the current therapeutic developmental pipeline of Longevity Biotech, Inc’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

 

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

 

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

 

Scope

 

The report provides brief overview of Longevity Biotech, Inc including business description, key information and facts, and its locations and subsidiaries
The report reviews current pipeline of Longevity Biotech, Inc’s human therapeutic division and enlists all their major and minor projects
The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 
Special feature on out-licensed and partnered product portfolio
The report summarizes all the dormant and discontinued pipeline projects
Latest company statement 
Latest news and deals relating to the Longevity Biotech, Inc’s pipeline products

 

Reasons to buy

 

Evaluate Longevity Biotech, Inc’s strategic position with total access to detailed information on its product pipeline
Assess the growth potential of Longevity Biotech, Inc in its therapy areas of focus
Identify new drug targets and therapeutic classes in the Longevity Biotech, Inc’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
Develop strategic initiatives by understanding the focus areas of Longevity Biotech, Inc and exploit collaboration and partnership opportunities
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Plan mergers and acquisitions effectively by identifying the most promising pipeline of Longevity Biotech, Inc
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Explore the dormant and discontinued projects of Longevity Biotech, Inc and identify potential opportunities in those areas
Avoid Intellectual Property Rights related issues

 

Table of Contents
 

 

Table of Contents 2
List of Tables 4
List of Figures 4
Longevity Biotech, Inc Snapshot 5
Longevity Biotech, Inc Overview 5
Key Information 5
Key Facts 5
Longevity Biotech, Inc - Research and Development Overview 6
Key Therapeutic Areas 6
Longevity Biotech, Inc - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Longevity Biotech, Inc - Pipeline Products Glance 11
Longevity Biotech, Inc - Early Stage Pipeline Products 11
Preclinical Products/Combination Treatment Modalities 11
Discovery Products/Combination Treatment Modalities 12
Longevity Biotech, Inc - Drug Profiles 13
Synthetic Peptide to Agonize GLP1/GIP for Metabolic Disorders 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
Synthetic Peptide to Inhibit Glycoprotein 41 for HIV 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
Synthetic Peptides for Central Nervous System Disorders and Diabetic Neuropathy 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
Synthetic Peptide 1 for Cancer 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Synthetic Peptide 2 for Cancer 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Synthetic Peptide for Metabolic Disorders 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Synthetic Peptide to Agonize VIP for Small Cell Lung Cancer 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Synthetic Peptide to Agonize VPAC2 for Pulmonary Arterial Hypertension 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Synthetic Peptide to Antagonize VPAC1 for Breast and Colon Cancer 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Longevity Biotech, Inc - Pipeline Analysis 22
Longevity Biotech, Inc - Pipeline Products by Target 22
Longevity Biotech, Inc - Pipeline Products by Route of Administration 23
Longevity Biotech, Inc - Pipeline Products by Molecule Type 24
Longevity Biotech, Inc - Pipeline Products by Mechanism of Action 25
Longevity Biotech, Inc - Dormant Projects 26
Longevity Biotech, Inc - Locations And Subsidiaries 27
Head Office 27

 

Appendix 28
Methodology 28
Coverage 28
Secondary Research 28
Primary Research 28
Expert Panel Validation 28
Contact Us 28
Disclaimer 29


List of Tables
 

Longevity Biotech, Inc, Key Information 5
Longevity Biotech, Inc, Key Facts 5
Longevity Biotech, Inc - Pipeline by Indication, 2015 8
Longevity Biotech, Inc - Pipeline by Stage of Development, 2015 9
Longevity Biotech, Inc - Monotherapy Products in Pipeline, 2015 10
Longevity Biotech, Inc - Preclinical, 2015 11
Longevity Biotech, Inc - Discovery, 2015 12
Longevity Biotech, Inc - Pipeline by Target, 2015 22
Longevity Biotech, Inc - Pipeline by Route of Administration, 2015 23
Longevity Biotech, Inc - Pipeline by Molecule Type, 2015 24
Longevity Biotech, Inc - Pipeline Products by Mechanism of Action, 2015 25
Longevity Biotech, Inc - Dormant Developmental Projects,2015 26"


 

List of Figures
 

Longevity Biotech, Inc - Pipeline by Top 10 Indication, 2015 7
Longevity Biotech, Inc - Pipeline by Stage of Development, 2015 9
Longevity Biotech, Inc - Monotherapy Products in Pipeline, 2015 10
Longevity Biotech, Inc - Pipeline by Top 10 Target, 2015 22
Longevity Biotech, Inc - Pipeline by Top 10 Route of Administration, 2015 23
Longevity Biotech, Inc - Pipeline by Top 10 Molecule Type, 2015 24
Longevity Biotech, Inc - Pipeline Products by Top 10 Mechanism of Action, 2015 25

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)1500 View Pricing